Biotechnology

A new patent for 3D fibroblast spheroids could revolutionize chronic wound treatment, giving FibroBiologics a key edge in the burgeoning biotech market.

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

As Kyverna eyes a first-in-class approval for its CAR T-cell therapy, it brings in a legal and compliance veteran with a prosecutor's edge to clear the path.

A new pharma deal isn't just about medicine. It's about the AI-driven network set to dismantle the slow, costly system of drug discovery as we know it.

bioAffinity Technologies' new gene-silencing therapy kills common skin cancer cells in lab studies while leaving healthy cells untouched, hinting at a future without scars.

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

With new funding from top VCs, DropGenie is shrinking gene editing to power the next wave of AI-driven drug discovery using precious patient cells.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

With a key NSF grant and promising large-animal data, Endure Biotherapeutics' engineered 'native' bacteria may rewrite the playbook for PKU and beyond.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

In a cooling life science real estate market, a major lease for advanced manufacturing highlights the rise of radiopharmaceuticals and Boston's enduring industrial might.

Israel's Biond Biologics hires Dr. Giovanni Selvaggi, a seasoned drug developer, as CMO. The move signals a strategic shift to accelerate its unique 'first-in-class' immunotherapies through late-stage trials.

A startup just raised $5M for an AI that teaches cells to be better factories. It's a glimpse into a future of cheaper, faster advanced medicines for all.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

Genialis's new BioBridge platform uses AI to de-risk the $137B flow of oncology drugs from China to the West, a critical test of resilience.